<DOC>
	<DOCNO>NCT00310895</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose GRN163L administration treat patient refractory relapse solid tumor malignancy .</brief_summary>
	<brief_title>Safety Dose Study GRN163L Administered Patients With Refractory Relapsed Solid Tumor Malignancies</brief_title>
	<detailed_description>GRN163L telomerase template antagonist vitro vivo activity variety tumor model system . Telomerase enzyme active primarily tumor cell crucial indefinite growth tumor cell . Inhibition telomerase may result antineoplastic effect .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>18 year age old Male female Measurable evaluable solid tumor malignancy Relapsed , refractory , locally advanced , metastatic disease Disease refractory amenable standard therapy Karnofsky performance status 70100 % Life expectancy 3 month great Pregnant lactate woman Primary central nervous system ( CNS ) malignancy active CNS metastases Hematologic malignancy Chemotherapy within 4 week prior study Mitomycin C , nitrosoureas within 6 week prior study High dose chemotherapy stem cell support within 6 month prior study Signal transduction inhibitor , monoclonal antibody , etc . within 4 week prior study Systemic hormonal therapy within 4 week prior study Anticoagulant therapy , antiplatelet therapy within 2 week prior study Radiotherapy within 4 week prior study Significant cardiovascular disease Serious/active infection Major surgical procedure within 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
</DOC>